Holen Sie sich die Stockscreener-App
14.89
1.13%
0.18
Schlusskurs vom Vortag:
$14.71
Offen:
$14.86
24-Stunden-Volumen:
741.11K
Relative Volume:
0.40
Marktkapitalisierung:
$45.01B
Einnahmen:
$30.25B
Nettoeinkommen (Verlust:
$1.37B
KGV:
34.98
EPS:
0.4257
Netto-Cashflow:
$5.08B
1W Leistung:
+4.03%
1M Leistung:
-2.07%
6M Leistung:
+5.13%
1J Leistung:
+12.36%
1-Tages-Spanne:
$14.82
$14.95
1-Wochen-Bereich:
$14.50
$14.95
52-Wochen-Spanne:
$12.57
$15.37
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Vergleichen Sie TAK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.88 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
ZTS
Zoetis Inc
|
146.62 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.21 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.32 | 15.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
287.10 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Eingeleitet | Cowen | Market Perform |
| 2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance
Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN
Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo
PD Stock on the Rise: A Promising Investment - The InvestChronicle
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Charles Schwab Trying To Close In On Key Technical Measure - Inkl
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN
Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN
Vyvanse Leaks: Beyond The Headlines - truthorfiction.com
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR
Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News
Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News
Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily
Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily
GFL Shares Experience Surge in Value - Knox Daily
UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily
Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News
Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater
Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition - MSN
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):